Recombinant human soluble thrombomodulin reduces the severity and incidence of necrotizing enterocolitis in a newborn rat model

[1] Neu J(2011)Necrotizing enterocolitis N Engl J Med. 364 255-264

[2] Walker WA(2013)Long term healthcare costs of infants who survived neonatal necrotizing enterocolitis: a retrospective longitudinal study among infants enrolled in Texas Medicaid BMC Pediatr. 13 127-928

[3] Ganapathy V(2014)Animal models of gastrointestinal and liver diseases. Animal models of necrotizing enterocolitis: pathophysiology, translational relevance, and challenges Am J Physiol Gastrointest Liver Physiol. 306 G917-16

[4] Hay JW(2015)Pathogenesis of necrotizing enterocolitis: modeling the innate immune response Am J Pathol. 185 4-431

[5] Kim JH(2012)Thrombomodulin links coagulation to inflammation and immunity Curr Drug Targets. 13 421-721

[6] Lee ML(1999)Recombinant thrombomodulin and activated protein C in the treatment of disseminated intravascular coagulation Thromb Haemost. 82 718-2186

[7] Rechtman DJ(2009)Recombinant human soluble thrombomodulin decreases the plasma high-mobility group box-1 protein levels, whereas improving the acute liver injury and survival rates in experimental endotoxemia Crit Care Med. 37 2181-80

[8] Lu P(2017)Thrombomodulin attenuates inflammatory damage due to liver ischemia and reperfusion injury in mice in toll-like receptor 4-dependent manner Am J Transplant. 17 69-65

[9] Sodhi CP(2014)Inflammatory signaling in NEC: role of NF-κB, cytokines and other inflammatory mediators Pathophysiology. 21 55-239

[10] Jia H(2015)Recombinant human soluble thrombomodulin improved lipopolysaccharide/d-galactosamine-induced acute liver failure in mice J Pharmacol Sci. 129 233-712

[1] Neu J(2011)Necrotizing enterocolitis N Engl J Med. 364 255-264

[2] Walker WA(2013)Long term healthcare costs of infants who survived neonatal necrotizing enterocolitis: a retrospective longitudinal study among infants enrolled in Texas Medicaid BMC Pediatr. 13 127-928

[3] Ganapathy V(2014)Animal models of gastrointestinal and liver diseases. Animal models of necrotizing enterocolitis: pathophysiology, translational relevance, and challenges Am J Physiol Gastrointest Liver Physiol. 306 G917-16

[4] Hay JW(2015)Pathogenesis of necrotizing enterocolitis: modeling the innate immune response Am J Pathol. 185 4-431

[5] Kim JH(2012)Thrombomodulin links coagulation to inflammation and immunity Curr Drug Targets. 13 421-721

[6] Lee ML(1999)Recombinant thrombomodulin and activated protein C in the treatment of disseminated intravascular coagulation Thromb Haemost. 82 718-2186

[7] Rechtman DJ(2009)Recombinant human soluble thrombomodulin decreases the plasma high-mobility group box-1 protein levels, whereas improving the acute liver injury and survival rates in experimental endotoxemia Crit Care Med. 37 2181-80

[8] Lu P(2017)Thrombomodulin attenuates inflammatory damage due to liver ischemia and reperfusion injury in mice in toll-like receptor 4-dependent manner Am J Transplant. 17 69-65

[9] Sodhi CP(2014)Inflammatory signaling in NEC: role of NF-κB, cytokines and other inflammatory mediators Pathophysiology. 21 55-239

[10] Jia H(2015)Recombinant human soluble thrombomodulin improved lipopolysaccharide/d-galactosamine-induced acute liver failure in mice J Pharmacol Sci. 129 233-712